LFB works for « the France of tomorrow » and unveils a new industrial project in Alès
EMA acceptance for filing of the MARKETING AUTHORISATION application FOR EPTACOG BETA, THE LFB RECOMBINANT FACTOR VIIA , AND PUBLICATION OF THE EXPLORATORY IN VITRO STUDY RESULTS on eptacog beta in combination with emicizumab
World Hemophilia Day : LFB's employees are committed
LFB research Grant in Immunology 2021 is open for applications
Take a look at the new LFB corporate brochure!
LFB opens the doors of the future Arras Factory
LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA'S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19
LFB announces FDA approval of SEVENFACT®, a recombinant coagulation Factor VIIa
BIOPRODUCTION SITES in the world
IN THE FIELD OF PLASMA-DERIVED MEDICINAL PRODUCTS
of LFB’s biomedicinal products are intended for the treatment of patients with rare diseases
- Intensive Care
The LFB 2021 coporate Brochure in video
LFB Arras plant under construction in October 2020 in video
LFB’s commitment to patients, with AFNP
LFB's commitment to patients and to IRIS association.